A metabolomics‐based molecular pathway analysis of how the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Skander Mulder, Ann Hammarstedt, Sunil B. Nagaraj, Viji Nair, Wenjun Ju, Jonatan Hedberg, Peter J. Greasley, Jan W. Eriksson, Jan Oscarsson, Hiddo J. L. Heerspink

Journal title: Diabetes, Obesity and Metabolism

Journal number: 22/7

Journal publisher: Blackwell Publishing Inc.

Published year: 2020

Published pages: 1157-1166

DOI identifier: 10.1111/dom.14018

ISSN: 1462-8902